Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 165.72 8.3 (5.27%) Market Cap: 20.96 Bil Enterprise Value: 19.89 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 67/100

Alnylam Pharmaceuticals Inc at Leerink Global Healthcare Conference Transcript

Feb 27, 2020 / 02:30PM GMT
Release Date Price: $112.49 (-4.71%)
Mani Foroohar
SVB Leerink LLC, Research Division - MD of Genetic Medicines & Senior Research Analyst

Good morning. I'm Mani Foroohar, managing director and senior analyst, genetic medicines here at SVB Leerink. And I am very fortunate to be joined by Yvonne Greenstreet, COO of Alnylam Pharmaceuticals.

Yvonne, do you want to start with a couple of quick slides and overview?

Yvonne Greenstreet
Alnylam Pharmaceuticals, Inc. - Executive VP & COO

Yes, sounds like a great idea. First of all, good morning, everybody. I'm absolutely delighted to be here. Glad we can still travel to conferences for now anyway. Obviously, there's the usual forward-looking statements that you can read on the screen.

We're really excited at Alnylam to be the pioneers in translating Nobel Prize-winning science into a product engine for sustainable innovation. And I think one of the remarkable things about our approach is the reproducible and modular approach that we've developed. And focusing on genetically validated targets has allowed us to deliver success

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot